The use of herbal medicines is expanding rapidly worldwide, but regional regulatory systems vary greatly, leading to variations in quality, safety and efficacy. Varying legal frameworks, insufficient quality control and gaps in post-market surveillance create challenges in ensuring the reliability of herbal products. This study aims to analyze and compare the regulations that oversee herbal medicines in five major regions: India, China, Europe, the United States and Japan, highlighting key challenges and proposing recommendations for improving global regulatory alignment. Data were collected from official regulatory websites and scholarly articles. Additionally, the study tracked the progress of related regulations, advancements in scientific research, and the evolving infrastructure in the respective five geographical areas. The study examined regulatory components, including licensing requirements, pre-market validation, quality control and post-market surveillance across these five regions. Regulatory approaches vary significantly: Europe and Japan emphasize pre-market validation and scientific evidence, while the U.S. relies more on post-market monitoring. India and China integrate traditional practices with modern regulatory frameworks. These differences pose challenges for ensuring consistent safety and quality standards globally. Potential solutions involve adopting Good Manufacturing Practices (GMPs), harmonizing pharmacopoeial standards and leveraging emerging technologies such as artificial intelligence for quality assurance and supply chain transparency. Achieving global regulatory harmonization is crucial for ensuring the safety and efficacy of herbal medicines while preserving traditional knowledge. Strengthening international collaboration, enforcing standardized quality measures, and integrating scientific validation into traditional systems can enhance consumer confidence and facilitate international trade in herbal medicines.
Pawar et al. (2026) studied this question.